Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Tryptamine Therapeutics ( (AU:TYP) ) has issued an update.
Tryptamine Therapeutics has announced the release of several unlisted options from escrow, which will remain unquoted unless exercised. This move is part of their ongoing efforts to enhance their financial flexibility and operational strategy. The company continues to advance its clinical trials, including a completed Phase 2a trial for binge eating disorder and ongoing trials for fibromyalgia and irritable bowel syndrome, utilizing their TRP-8802 and TRP-8803 formulations.
More about Tryptamine Therapeutics
Tryp Therapeutics is a clinical-stage biopharmaceutical company focusing on developing proprietary formulations of psilocin combined with psychotherapy to address diseases with unmet medical needs. Their lead product, TRP8803, is an innovative IV-infused psilocin formulation aimed at improving the efficacy and safety of psychedelic-assisted psychotherapy.
Average Trading Volume: 1,737,406
Technical Sentiment Signal: Buy
Current Market Cap: A$51.8M
For a thorough assessment of TYP stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue